LON:VAL ValiRx (VAL) Share Price, News & Analysis → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free VAL Stock Alerts GBX 3.30 -0.15 (-4.35%) (As of 04:13 PM ET) Add Compare Share Share Today's Range 3.23▼ 3.4650-Day Range 3.42▼ 4.8552-Week Range 3.23▼ 15Volume607,805 shsAverage Volume764,257 shsMarket Capitalization£4.37 millionP/E RatioN/ADividend Yield0.63%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get ValiRx alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. About ValiRx Stock (LON:VAL)ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.Read More VAL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAL Stock News HeadlinesFebruary 28, 2024 | msn.comNew method discovered to halt active cancer cellsFebruary 27, 2024 | uk.news.yahoo.comScientists discover 'two-punch' method to eliminate cancer cellsApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) February 13, 2024 | lse.co.ukValiRx says requisition notice from shareholder group is invalidFebruary 9, 2024 | lse.co.ukTRADING UPDATES: ValiRx receives shareholder request for board changeDecember 5, 2023 | markets.businessinsider.comEuropean Stocks Close Mostly HigherDecember 5, 2023 | markets.businessinsider.comEuropean Markets Move Mostly HigherDecember 5, 2023 | lse.co.ukValiRx says ValiSeek inks deal to licence VAL401 drug with AmbroseApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) November 15, 2023 | morningstar.comValiRx PLC EAJFNovember 10, 2023 | lse.co.ukValiRx signs deal to evaluate StingRay Bio drug candidatesOctober 6, 2023 | lse.co.ukCORRECT (Oct 5): ICG Enterprise ups interim payout on better resultsOctober 6, 2023 | lse.co.ukValiRx sees no reason for shares jump; notes TheoremRx mulls mergerSeptember 11, 2023 | finance.yahoo.comVAL.L - ValiRx plcAugust 24, 2023 | lse.co.ukValiRx interim loss widens as costs increase; hails Inaphaea progressAugust 24, 2023 | marketwatch.comValiRx Shares Rise on Higher Income Expectations From Inaphaea BioLabsAugust 14, 2023 | lse.co.ukValiRx signs collaborative services agreement with AgilityAugust 14, 2023 | marketwatch.comValiRx Shares Rise After Collaborative Services Agreement With AgilityJuly 19, 2023 | marketwatch.comValiRx Shares Rise After Subsidiary Secures ContractJune 28, 2023 | lse.co.ukTRADING UPDATES: All Things Considered raises funds to buy SandbagJune 16, 2023 | lse.co.ukValiRx shares drop after cancer drug research droppedJune 16, 2023 | marketwatch.comValiRx Shares Fall After Cancer-Drug Development AbandonedJune 8, 2023 | marketwatch.comValiRx Changes IP Exclusivity Terms With TheoremRx to Exclude Greater ChinaJune 7, 2023 | lse.co.ukValiRx expands cancer research agreement with University of BarcelonaJune 3, 2023 | lse.co.ukSelf Storage Gr Share ChatMay 4, 2023 | msn.comMilner Therapeutics Institute welcomes Cathy Tralau-Stewart as executive directorMarch 26, 2023 | marketwatch.comGlobal Endometriosis Drugs Market Research Growth, Regions, Type and Application, Forecast Analysis to 2023-2030 By VMReportsSee More Headlines Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/07/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:VAL CUSIPN/A CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.39% Return on Assets-47.22% Debt Debt-to-Equity Ratio0.73 Current Ratio13.37 Quick Ratio1.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.05 per share Price / Cash Flow62.50 Book ValueGBX 4 per share Price / Book0.83Miscellaneous Outstanding Shares132,350,000Free FloatN/AMarket Cap£4.37 million OptionableNot Optionable Beta0.63 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Suzanne J. Dilly B.Sc. (Age 46)BSc, Ph.D., CEO & Director Comp: $160.85kMr. James Gerry Desler FCA (Age 79)CFO, Company Secretary & Executive Director Comp: $53kMr. Kumar NawaniHead of OperationsDr. Catherine Jane Tralau-Stewart Ph.D.Chief Scientific Officer & Board ObserverMr. Tarquin EdwardsHead of Investor Relations & CommunicationsMr. Mark TreharneCorporate Development ManagerMore ExecutivesKey CompetitorsIXICOLON:IXIBSF EnterpriseLON:BSFAOxford Cannabinoid TechnologiesLON:OCTPGenflow BiosciencesLON:GENFFusion AntibodiesLON:FABView All Competitors VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed in 2024? ValiRx's stock was trading at GBX 5.90 on January 1st, 2024. Since then, VAL stock has decreased by 44.1% and is now trading at GBX 3.30. View the best growth stocks for 2024 here. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) announced its quarterly earnings data on Monday, September, 7th. The company reported ($4.43) earnings per share for the quarter. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR). How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:VAL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThese AI trades triggered this morning (545% return)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
